Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long term lenalidomide therapy: incidence and prognostic significance.

08:00 EDT 23rd April 2013 | BioPortfolio

Summary of "Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long term lenalidomide therapy: incidence and prognostic significance."

No Summary Available


Department of Medicine, Division of Hematologic Malignancies.

Journal Details

This article was published in the following journal.

Name: Leukemia
ISSN: 1476-5551


PubMed Articles [41846 Associated PubMed Articles listed on BioPortfolio]

Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.

Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA ...

Correlation of WT1 and VEGF Expression with Angiogenesis in Bone Marrow Biopsies of Multiple Myeloma Patients.

To investigate the relationship of WT1 and VEGF expression with angiogenesis in bone marrow biopsies of multiple myeloma patients.

Detection of Molecular Cytogenetic Aberrations by Fluorescence in Situ Hybridization in Different Bone Marrow Samples of Multiple Myeloma.

To detect the molecular cytogenetic abnormalities in different bone marrow samples of multiple myeloma by using fluorescence in situ hybridization (FISH) technology. The bone marrow cells from 48 case...

Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.

Alterations and senescence in bone marrow mesenchymal stromal cells of multiple myeloma patients (MM-BMMSCs) have become an important research focus. However the role of senescence in the pathophysiol...

State-of-the-art of bone marrow imaging in multiple myeloma.

Multiple myeloma is a common hematological malignancy arising in the bone marrow. Bone lesions were initially depicted with conventional radiography, although recently F-FDG PET/CT and MRI are recogni...

Clinical Trials [5890 Associated Clinical Trials listed on BioPortfolio]

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. ...

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with multiple myeloma that has recurred following bone marrow transplantation. PURPOSE: This phase II...

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

The primary objective is to cure multiple myeloma with less toxic allogeneic bone marrow transplantation while inducing renal allograft tolerance through mixed chimerism in patients with e...

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

Patients will have immune cells collected and then expanded outside of the body. Patients will undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell...

Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma

Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions ev...

Medical and Biotech [MESH] Definitions

Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.

A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.

Abnormal immunoglobulins characteristic of MULTIPLE MYELOMA.

An abnormal protein with unusual thermosolubility characteristics that is found in the urine of patients with MULTIPLE MYELOMA.

Multiple protein bands serving as markers of specific ANTIBODIES and detected by ELECTROPHORESIS of CEREBROSPINAL FLUID or serum. The bands are most often seen during inflammatory or immune processes and are found in most patients with MULTIPLE SCLEROSIS.